Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia

Oliver Giles Best, PhDBSc, Kyle Crassini, MBBS BSc, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA

Blood (2014) 124 (21): 4693.

https://doi.org/10.1182/blood.V124.21.4693.4693

Published: 2014

Journal Articles

Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma

Mairead Reidy, PhD, Marianne vanDijk, PhD, Niamh Keane, MB BCh BAO, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath

Blood (2014) 124 (21): 5713.

https://doi.org/10.1182/blood.V124.21.5713.5713

Published: 2014

Journal Articles

Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model

Alessandro Natoni, PhD, Michele Moschetta, MD, Siobhan Glavey, MD, Ping Wu, MBBS, MSc, Gareth J. Morgan, MD PhD, Lokesh Joshi, PhD, John L. Magnani, PhD, Irene M. Ghobrial, MD, Michael E O'Dwyer, MD FRCPI, FRCPath

Blood (2014) 124 (21): 4718.

https://doi.org/10.1182/blood.V124.21.4718.4718

Published: 2014

Journal Articles

Low Expression Of The FUCA1 Gene Is An Adverse Prognostic Factor In Myeloma and Combined With High Sialyltransferase Gene Expression Identifies Patients At Increased Risk Of Early Disease Progression and Death

Siobhan Glavey, MD, Ping Wu, MBBS, MSc, Laura S Murillo, PhD, Catherine Loughrey, MSc, Aldo M Roccaro, MD, PhD, Gareth J Morgan, MD PhD, Irene M. Ghobrial, MD, Lokesh Joshi, PhD, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 1864.

https://doi.org/10.1182/blood.V122.21.1864.1864

Published: 2013

Journal Articles

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Janusz Krawczyk, MD, MRCP, Sahar Khan, Bushra Ahsan, Larissa Higgins, Enda McGowan, Safa Eltom, Khalid Awad Saeed, Carmelita Gibbons, Karen Maloney, Teresa Meenaghan, Geraldine Walpole, Catriona Collins, Robert Snedker, Moutaz Abdelrahmen, Amjad Hayat, MBBS, PhD, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Margaret Murray, MD, MRCPath, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 5396.

https://doi.org/10.1182/blood.V122.21.5396.5396

Published: 2013

Journal Articles

Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo

Siobhan Glavey, MD, Salomon Manier, MD, Antonio Sacco, BS, Michaela R Reagan, PhD, Yuji Mishima, PhD, Yong Zhang, PhD, Ilyas Sahin, MD, Yu Zhang, MD, Wenjing Zhang, MD, Laura S Murillo, PhD, Catherine Loughrey, MSc, Alessandro Natoni, PhD, Katarzyna Kazlowska, Lokesh Joshi, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 275.

https://doi.org/10.1182/blood.V122.21.275.275

Published: 2013

Journal Articles

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, Andrew Spencer, MD, Heather J. Sutherland, MD, PhD, FRCPC, Michael E O'Dwyer, MD, FRCPI, FRCPath, Shang-Yi Huang, MD, PhD, Keith Stewart, MBA, MB, CHB, Ajai Chari, MD, Michael Rosenzwieg, MD, Ajay K. Nooka, MD, MPH, Cara A Rosenbaum, MD, Craig C Hofmeister, MD, Deborah A Smith, PharmD, Joyce M Antal, Ademi Santiago-Walker, Jennifer Gauvin, Joanna B Opalinska, Suzanne Trudel, MD

Blood (2013) 122 (21): 283.

https://doi.org/10.1182/blood.V122.21.283.283

Published: 2013

Journal Articles

Glycosylation-Related Gene Expression Is Dysregulated in Multiple Myeloma and Overexpression of the Sialyltransferase ST3GAL6 Is Associated with Inferior Survival.

Siobhan V Glavey, M.B., BCh, BAO, BSc, Stephen Cunningham, PhD, Laura S Murillo, PhD, Catherine Loughrey, MSc, Ping Wu, MBBS, MSc, Michael Cairns, PhD, Satbir Kaur Gill, MSc, Anja Kruger, MSc, Jared Q Gerlach, PhD, Marian Kane, PhD, Gareth J. Morgan, MD PhD, Lokesh Joshi, PhD, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2012) 120 (21): 2931.

https://doi.org/10.1182/blood.V120.21.2931.2931

Published: 2012

Journal Articles

Examining Measures of Proliferation for Use in Risk Stratification of Myeloma

Mark R.E. Coyne, MBBCh, BAO, MRCPI, Linda Wellik, Esteban Braggio, PhD, Michael E O'Dwyer, MD, FRCPI, FRCPath, Corrado Santocanale, PhD, Riccardo Valdez, MD, P.Leif Bergsagel, MD, Marta Chesi

Blood (2011) 118 (21): 5093.

https://doi.org/10.1182/blood.V118.21.5093.5093

Published: 2011

Journal Articles

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Michael E O'Dwyer, MD, FRCPI, FRCPath, Ronan Swords, MD, MRCPI, FRCPath, Francis Giles, MD FRCPI FRCPath, Mary Frances McMullin, MD, Philipp D. le Coutre, MD, Arnon Nagler, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Karine Egan, Brian Moulton, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD

Blood (2011) 118 (21): 3774.

https://doi.org/10.1182/blood.V118.21.3774.3774

Published: 2011

Journal Articles

Targeting Cdc7 Kinase in Multiple Myeloma.

Mark R.E. Coyne, MBBCh, BAO, MRCPI, Seán Naughton, Patrick J Hayden, MD, MRCPath, Alessia Montagnoli, PhD, Michael E O'Dwyer, MD, FRCPI, FRCPath, Corrado Santocanale, PhD

Blood (2009) 114 (22): 3847.

https://doi.org/10.1182/blood.V114.22.3847.3847

Published: 2009

NARROW

Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia

Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma

Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model

Low Expression Of The FUCA1 Gene Is An Adverse Prognostic Factor In Myeloma and Combined With High Sialyltransferase Gene Expression Identifies Patients At Increased Risk Of Early Disease Progression and Death

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Glycosylation-Related Gene Expression Is Dysregulated in Multiple Myeloma and Overexpression of the Sialyltransferase ST3GAL6 Is Associated with Inferior Survival.

Examining Measures of Proliferation for Use in Risk Stratification of Myeloma

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Targeting Cdc7 Kinase in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only